Respiratory Disorder TRIZ Cases

Apelin receptor agonists help preserve endothelial cells and capillary architecture in IPF, reducing inflammation and slowing fibrotic decline.

Compound I restores CFTR trafficking and channel activity to improve anion transport, reduce mucus buildup, and ease cystic fibrosis symptoms.

Controlled heat-drying boosts parsnip polyphenols before extraction, improving antioxidant and anti-inflammatory activity for respiratory disease care.

A deuterated CFTR modulator combined with other CFTR agents improves protein trafficking and channel activity to ease cystic fibrosis symptoms.

Oral acebilustat inhibits LTA4-h to cut pulmonary exacerbations and inflammation in cystic fibrosis while limiting infection risk.

Corrector and potentiator compounds address CFTR trafficking and gating defects to restore anion transport and reduce mucus buildup.

Selective EPAC1 inhibitors reduce lung fibrosis markers and fibroblast proliferation, offering a targeted approach for idiopathic pulmonary fibrosis.

Istradefylline, a selective A2A antagonist, modulates Wnt/β-catenin signaling to reduce fibroblast activity and collagen deposition.

Engineered extracellular vesicles deliver let-7i-5p miRNA to reduce ARDS lung injury and inflammation beyond supportive care.

This PAH case pairs ralinepag with riociguat to reduce dose escalation and support efficacy with fewer administration demands.

This case stabilizes phenylephrine in respiratory formulations through pH 2–5 control, aldehyde removal, chelators, and reducing agents.

This case combines domain-specific CFTR correctors and potentiators to stabilize ΔF508-CFTR and improve chloride transport.

Combining ralinepag with cGMP-elevating agents or prostanoids may improve PAH efficacy while reducing titration and dosing frequency.

Compound I combines CFTR correctors and potentiators to improve protein trafficking, channel activity, and ion transport in cystic fibrosis.

This case uses Compound I as a CFTR modulator to address defective ion and fluid transport in cystic fibrosis.

Merging isothiocyanate and biguanide agents addresses multi-action mechanism limitations by reducing TGF-beta1, fibronectin, and AGE protein markers.

Targeting SHMT2 and MTHFD2 normalizes the NAD/NADH ratio to resolve cellular stress from impaired electron transport chain activity.

Early ambrisentan administration improves exercise capacity and delays clinical worsening in recent pulmonary hypertension diagnoses.

2,6-diaminopurine promotes transreading at premature stop codons to restore protein expression while minimizing toxicity found in existing activators.

Chromenone derivatives induce modified HSP27 dimers to block chaperone activity, treating radiation-induced pulmonary fibrosis.

A pharmaceutical composition containing Agastache rugosa and licorice extracts inhibits TRPV1, CXCR1, CXCR2, and MUC5AC activities to reduce respiratory symptoms.

A GaInNAsSb compound base layer reduces electrical resistance in Gallium Arsenide heterojunction bipolar transistors.

Composite herbal formulation addresses side effects of glucocorticoids by improving arterial blood qi and pulmonary function in interstitial pulmonary fibrosis.

Repurposing antihypertensive drugs blocks insulin-like growth factor signaling, bypassing lengthy new drug development timelines while ensuring clinical safety.

Combining farnesyltransferase inhibitors with kinase inhibitors targets drug-tolerant persister cells in cancer treatment.

Dual targeting of EGFR signaling and CBP/p300 transcriptional programs delays resistance onset in EGFR-mutant NSCLC patients.

A composite plant extract increases body weight and reduces lung coefficient in rat models.

Inhaled braylin reduces inflammatory cell counts, cytokine levels, and mucus production in the lungs while avoiding systemic toxicity.

Administering veliparib alongside carboplatin and paclitaxel addresses unique smoking-induced DNA damage profiles, improving progression-free survival.

Administering an AGTR2 antagonist restores respiratory compliance and elastance, addressing impaired pulmonary mechanics in cystic fibrosis patients.

FENDRR lncRNA binds IRP1 and competes with miR-214 to reduce collagen production and attenuate pulmonary fibrosis.

Applying preliminary action via timed corticosteroid dosing schedules to mitigate structural lung damage and respiratory symptoms from SARS-CoV-2 exposure.

Calcium chloride precipitation removes polysaccharides from Quillaja extracts, cutting production time from two months while maintaining high purity.

Selective cathepsin K inhibitors reduce right ventricular hypertrophy by blocking protease activity, addressing side effects of existing therapies.

Replacing hydrogen with deuterium strengthens carbon bonds to reduce toxic metabolite formation and improve cystic fibrosis treatment outcomes.

FASN inhibitors treat pulmonary fibrosis by reducing profibrotic gene expression and improving lung function.

Topical hyaluronic acid forms a protective film on respiratory mucosa to hydrate and shield irritated tissue surfaces.

Oral dexpramipexole targets JAK1 signaling to lower eosinophils and exacerbations despite existing ICS and LABA therapy.

Amino acid compositions increase CFTR protein translocation to the plasma membrane, addressing costly Phe508del mutation treatments.

Anti-CELA1 antibodies neutralize harmful protease activity, preventing progressive airspace destruction and respiratory insufficiency.

Dispersing agents convert solid methacrylate copolymers into aqueous dispersions below 45°C, eliminating high-temperature heating requirements.

A therapeutic foot patch delivers cough-reducing active ingredients through transdermal absorption to provide relief.

Administers SGLT or Na+/K+-ATPase inhibitors alongside reduced elexacaftor, tezacaftor, and ivacaftor doses to treat class I CFTR mutations.

Pharmaceutical combination of PDE5 inhibitor, arginine, and N-acetylcysteine scavenges free radicals to protect blood vessels.

Optimized TRPM8 modulators provide prolonged cooling sensations while reducing skin irritation and improving solubility.

Composite herbal formulation extends telomere length to address progressive respiratory disease mechanisms.

Combines DYRK1 and EGFR inhibitors to eliminate quiescent cancer cells, overcoming treatment resistance caused by cell dormancy.

Zirconium addition refines copper alloy grains, reducing lead content while maintaining machinability and strength.

Alginate oligomers reduce mucus viscosity to overcome the barrier preventing CFTR modulators from reaching epithelial cells.